{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:28:32Z","timestamp":1761708512845},"reference-count":41,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Invasive disease caused by meningococcal capsular groups A, C, W-135, and Y is now preventable by means of glycoconjugate vaccines that target their respective polysaccharide capsules. The capsule of group B meningococci (MenB) is poorly immunogenic and may induce autoimmunity. Vaccines based on the major immunodominant surface porin, PorA, are effective against clonal epidemics but, thus far, have a limited scope of coverage against the wider MenB population at large. In an alternative approach, the first-generation, investigational, recombinant MenB (rMenB) plus outer membrane vesicle (OMV) (rMenB-OMV) vaccine contains a number of relatively conserved surface proteins, fHBP, NHBA (previously GNA2132), and NadA, alongside PorA P1.4-containing OMVs from the New Zealand MeNZB vaccine. MenB currently accounts for approximately 90% of cases of meningococcal disease in England and Wales. To assess potential rMenB-OMV vaccine coverage of pathogenic MenB isolates within this region, all English and Welsh MenB case isolates from January 2008 (\n            <jats:italic>n<\/jats:italic>\n            = 87) were genetically characterized with respect to fHBP, NHBA, NadA, and PorA. Alleles for\n            <jats:italic>fHbp<\/jats:italic>\n            ,\n            <jats:italic>nhba<\/jats:italic>\n            , and\n            <jats:italic>porA<\/jats:italic>\n            were identified in all of the isolates, of which 22% were also found to harbor\n            <jats:italic>nadA<\/jats:italic>\n            alleles. On the basis of genotypic data and predicted immunological cross-reactivity, the potential level of rMenB-OMV vaccine coverage in England and Wales ranges from 66% to 100%.\n          <\/jats:p>","DOI":"10.1128\/cvi.00027-10","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T02:20:49Z","timestamp":1270693249000},"page":"919-929","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":89,"title":["Characterization\n            <i>of fHbp<\/i>\n            ,\n            <i>nhba<\/i>\n            (\n            <i>gna2132<\/i>\n            ),\n            <i>nadA<\/i>\n            ,\n            <i>porA<\/i>\n            , and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine"],"prefix":"10.1128","volume":"17","author":[{"given":"Jay","family":"Lucidarme","sequence":"first","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Comanducci","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward B.","family":"Kaczmarski","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Guiver","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela J.","family":"Vallely","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Bambini","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Muzzi","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"},{"name":"Novartis Vaccines, Siena, Italy"},{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.vaccine.2009.02.098","volume":"27","year":"2009","unstructured":"Bambini, S., A. Muzzi, P. Olcen, R. Rappuoli, M. Pizza, and M. Comanducci. 2009. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine27:2794-2803.","journal-title":"Vaccine"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","volume":"338","year":"1991","unstructured":"Bjune, G., E. A. H\u00f8iby, J. K. Gr\u00f8nnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. N\u00f8kleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Froholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338:1093-1096.","journal-title":"Lancet"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","volume":"13","year":"1995","unstructured":"Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, and J. Mays. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outermembrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine13:821-829.","journal-title":"Vaccine"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","volume":"27","year":"2009","unstructured":"Campbell, H., R. Borrow, D. Salisbury, and E. Miller. 2009 Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine27(Suppl. 2):B20-B29.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","volume":"195","year":"2002","unstructured":"Comanducci, M., S. Bambini, B. Brunelli, J. Adu-Bobie, B. Aric\u00f2, B. Capecchi, M. M. Giuliani, V. Masignani, L. Santini, S. Savino, D. M. Granoff, D. A. Caugant, M. Pizza, R. Rappuoli, and M. Mora. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med.195:1445-1454.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.7.4217-4223.2004"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2958.1998.01101.x","volume":"30","year":"1998","unstructured":"Feavers, I. M., and M. C. Maiden. 1998. A gonococcal porA pseudogene: implications for understanding the evolution and pathogenicity of Neisseria gonorrhoeae. Mol. Microbiol.30:647-656.","journal-title":"Mol. Microbiol."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.vaccine.2004.11.029","volume":"23","year":"2005","unstructured":"Findlow, J., A. Lowe, S. Deane, P. Balmer, G. van den Dobbelsteen, M. Dawson, N. Andrews, and R. Borrow. 2005. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine23:2623-2627.","journal-title":"Vaccine"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.4.2088-2100.2004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","volume":"103","year":"2006","unstructured":"Giuliani, M. M., J. Adu-Bobie, M. Comanducci, B. Aric\u00f2, S. Savino, L. Santini, B. Brunelli, S. Bambini, A. Biolchi, B. Capecchi, E. Cartocci, L. Ciucchi, F. Di Marcello, F. Ferlicca, B. Galli, E. Luzzi, V. Masignani, D. Serruto, D. Veggi, M. Contorni, M. Morandi, A. Bartalesi, V. Cinotti, D. Mannucci, F. Titta, E. Ovidi, J. A. Welsch, D. Granoff, R. Rappuoli, and M. Pizza. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A.103:10834-10839.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","volume":"55","year":"2006","unstructured":"Gray, S. J., C. L. Trotter, M. E. Ramsay, M. Guiver, A. J. Fox, R. Borrow, R. H. Mallard, and E. B. Kaczmarski. 2006. Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol.55:887-896.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_13_2","first-page":"95","volume":"41","year":"1999","unstructured":"Hall, T. A. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT. Nucleic Acids Symp.41:95-98.","journal-title":"Nucleic Acids Symp."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","volume":"27","year":"2009","unstructured":"Harrison, L. H., C. L. Trotter, and M. E. Ramsay. 2009. Global Epidemiology of meningococcal disease. Vaccine27(Suppl. 2):B51-B63.","journal-title":"Vaccine"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.vaccine.2005.11.006","volume":"24","year":"2006","unstructured":"Jacobsson, S., S. Thulin, P. M\u00f6lling, M. Unemo, M. Comanducci, R. Rappuoli, and P. Olc\u00e9n. 2006. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine24:2161-2168.","journal-title":"Vaccine"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","volume":"166","year":"2007","unstructured":"Kelly, C., R. Arnold, Y. Galloway, and J. O'Hallahan. 2007. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol.166:817-823.","journal-title":"Am. J. Epidemiol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00936-09"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","volume":"177","year":"2006","unstructured":"Madico, G., J. A. Welsch, L. A. Lewis, A. McNaughton, D. H. Perlman, C. E. Costello, J. Ngampasutadol, U. Vogel, D. M. Granoff, and S. Ram. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol.177:501-510.","journal-title":"J. Immunol."},{"key":"e_1_3_2_19_2","unstructured":"Reference deleted."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.4.486-491.2006"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0264-410X(00)00047-5","volume":"18","year":"2000","unstructured":"Martin, S. L., R. Borrow, P. van der Ley, M. Dawson, A. J. Fox, and K. A. Cartwright. 2000. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine18:2476-2481.","journal-title":"Vaccine"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","volume":"197","year":"2003","unstructured":"Masignani, V., M. Comanducci, M. M. Giuliani, S. Bambini, J. Adu-Bobie, B. Arico, B. Brunelli, A. Pieri, L. Santini, S. Savino, D. Serruto, D. Litt, S. Kroll, J. A. Welsch, D. M. Granoff, R. Rappuoli, and M. Pizza. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med.197:789-799.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","volume":"27","year":"2009","unstructured":"McNeil, L. K., E. Murphy, X. J. Zhao, S. Guttmann, S. L. Harris, A. A. Scott, C. Tan, M. Mack, I. DaSilva, K. Alexander, K. Mason, H. Q. Jiang, D. Zhu, T. L. Mininni, G. W. Zlotnick, S. K. Hoiseth, T. R. Jones, M. W. Pride, K. U. Jansen, and A. S. Anderson. 2009. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine27:3417-3421.","journal-title":"Vaccine"},{"key":"e_1_3_2_24_2","unstructured":"Eur. Soc. Paediatr. Infect. Dis. 2008"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","volume":"200","year":"2009","unstructured":"Murphy, E., L. Andrew, K. L. Lee, D. A. Dilts, L. Nunez, P. S. Fink, K. Ambrose, R. Borrow, J. Findlow, M. K. Taha, A. E. Deghmane, P. Kriz, M. Musilek, J. Kalmusova, D. A. Caugant, T. Alvestad, L. W. Mayer, C. T. Sacchi, X. Wang, D. Martin, A. von Gottberg, M. du Plessis, K. P. Klugman, A. S. Anderson, K. U. Jansen, G. W. Zlotnick, and S. K. Hoiseth. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis.200:379-389.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_26_2","first-page":"52","year":"2009","unstructured":"Oster, P., D. Toneatta, P. Dull, K. Vienken, E. Ympa, L. DeTora, C. Webster, and L. Danzig. 2009. First use of an investigational meningococcal serogroup B vaccine administered in combination with New Zealand (NZ) strain (NZ98\/254) outer membrane vesicles (OMV) in healthy adults, p. 52-53. Abstr. Meningitidis Res. Found. Int. Conf. Meningitis Septicaemia Children Adults.","journal-title":"Meningitidis Res. Found. Int. Conf. Meningitis Septicaemia Children Adults"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/adc.2006.111500","volume":"92","year":"2007","unstructured":"Pace, D., and A. J. Pollard. 2007. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines. Arch. Dis. Child.92:909-915.","journal-title":"Arch. Dis. Child."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.vaccine.2005.01.056","volume":"23","year":"2005","unstructured":"Pillai, S., A. Howell, K. Alexander, B. E. Bentley, H. Q. Jiang, K. Ambrose, D. Zhu, and G. Zlotnick. 2005. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine23:2206-2209.","journal-title":"Vaccine"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","volume":"287","year":"2000","unstructured":"Pizza, M., V. Scarlato, V. Masignani, M. M. Giuliani, B. Aric\u00f2, M. Comanducci, G. T. Jennings, L. Baldi, E. Bartolini, B. Capecchi, C. L. Galeotti, E. Luzzi, R. Manetti, E. Marchetti, M. Mora, S. Nuti, G. Ratti, L. Santini, S. Savino, M. Scarselli, E. Storni, P. Zuo, M. Broeker, E. Hundt, B. Knapp, E. Blair, T. Mason, H. Tettelin, D. W. Hood, A. C. Jeffries, N. J. Saunders, D. M. Granoff, J. C. Venter, E. R. Moxon, G. Grandi, and R. Rappuoli. 2000. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science287:1816-1820.","journal-title":"Science"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00036-08"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","volume":"344","year":"2001","unstructured":"Rosenstein, N. E., B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes. 2001. Meningococcal disease. N. Engl. J. Med.344:1378-1388.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0378-1119(93)90001-J","volume":"137","year":"1993","unstructured":"Saunders, N. B., W. D. Zollinger, and V. B. Rao. 1993. A rapid and sensitive PCR strategy employed for amplification and sequencing of porA from a single colony-forming unit of Neisseria meningitidis. Gene137:153-162.","journal-title":"Gene"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","volume":"176","year":"2006","unstructured":"Schneider, M. C., R. M. Exley, H. Chan, I. Feavers, Y. H. Kang, R. B. Sim, and C. M. Tang. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol.176:7566-7575.","journal-title":"J. Immunol."},{"key":"e_1_3_2_35_2","first-page":"195","volume":"14","year":"1991","unstructured":"Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14:195-207.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2958.1994.tb01014.x","volume":"12","year":"1994","unstructured":"Suker, J., I. M. Feavers, M. Achtman, G. Morelli, J. F. Wang, and M. C. Maiden. 1994. The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Mol. Microbiol.12:253-265.","journal-title":"Mol. Microbiol."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msm092"},{"key":"e_1_3_2_38_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. H\u00f8iby, J. Holst, H. N\u00f8kleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1126\/science.287.5459.1809","volume":"287","year":"2000","unstructured":"Tettelin, H., N. J. Saunders, J. Heidelberg, A. C. Jeffries, K. E. Nelson, J. A. Eisen, K. A. Ketchum, D. W. Hood, J. F. Peden, R. J. Dodson, W. C. Nelson, M. L. Gwinn, R. DeBoy, J. D. Peterson, E. K. Hickey, D. H. Haft, S. L. Salzberg, O. White, R. D. Fleischmann, B. A. Dougherty, T. Mason, A. Ciecko, D. S. Parksey, E. Blair, H. Cittone, E. B. Clark, M. D. Cotton, T. R. Utterback, H. Khouri, H. Qin, J. Vamathevan, J. Gill, V. Scarlato, V. Masignani, M. Pizza, G. Grandi, L. Sun, H. O. Smith, C. M. Fraser, E. R. Moxon, R. Rappuoli, and J. C. Venter. 2000. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science287:1809-1815.","journal-title":"Science"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.vaccine.2006.09.025","volume":"25","year":"2007","unstructured":"van den Dobbelsteen, G. P., H. H. van Dijken, S. Pillai, and L. van Alphen. 2007. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine25:2491-2496.","journal-title":"Vaccine"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1086\/379375","volume":"188","year":"2003","unstructured":"Welsch, J. A., G. R. Moe, R. Rossi, J. Adu-Bobie, R. Rappuoli, and D. M. Granoff. 2003. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis.188:1730-1740.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","volume":"126","year":"1972","unstructured":"Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis.126:514-521.","journal-title":"J. Infect. Dis."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00027-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00027-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:43:03Z","timestamp":1627591383000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00027-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1128\/CVI.00027-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00027-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"2010-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-03-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}